Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS +11.82%·Rev n/aQ1 23EPS -6.03%·Rev n/aQ4 22EPS +3.52%·Rev n/aQ3 22EPS +13.19%·Rev n/a⚠ consensus missing

Natera, Inc. NTRA

Michael Brophy — Chief Financial Officer

Steve Chapman — Chief Executive Officer

Solomon Moshkevich — General Manager of Oncology

−1.2%1d on move date−0.9% vs SPY3d+16.1%5d+18.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTRA calls or request research access.

More NTRA calls Browse calls Request research access